Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Thacker EL, Jensen PN, Psaty BM, McKnight B, Longstreth WT, Dublin S, Newton KM, Smith NL, Siscovick DS, Heckbert SR. Use of statins and antihypertensive medications in relation to risk of long-standing persistent atrial fibrillation. Ann Pharmacother 2015;49:378-86. [PMID: 25628466 DOI: 10.1177/1060028014568447] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open

For:	Thacker EL, Jensen PN, Psaty BM, McKnight B, Longstreth WT, Dublin S, Newton KM, Smith NL, Siscovick DS, Heckbert SR. Use of statins and antihypertensive medications in relation to risk of long-standing persistent atrial fibrillation. Ann Pharmacother 2015;49:378-86. [PMID: 25628466 DOI: 10.1177/1060028014568447] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open

Number

Cited by Other Article(s)

Gatto NM, Renz A, Tom SE, Lyons M, Macuiba JA, Dodd TS, Lind BK, Gray SL, Meyers K, Larson EB, Nelson JC, McEvoy LK, Sankaran S, Key D, Litondo JA, Crane PK. The Adult Changes in Thought (ACT) Medical Records Abstraction Project: A Resource for Research on Biological, Psychosocial and Behavioral Factors on the Aging Brain and Alzheimer's Disease and Related Dementias. Brain Sci 2024;14:1075. [PMID: 39595838 PMCID: PMC11592130 DOI: 10.3390/brainsci14111075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2024] [Revised: 10/23/2024] [Accepted: 10/25/2024] [Indexed: 11/28/2024] Open

Affiliation(s)

Nicole M. Gatto Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Anne Renz Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Sarah E. Tom Columbia University Irving Medical Center, New York, NY 10032, USA;
Mary Lyons Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Jennifer A. Macuiba Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Tammy S. Dodd Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Bonnie K. Lind Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Shelly L. Gray School of Pharmacy, University of Washington, Seattle, WA 98102, USA;
Kelly Meyers Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Eric B. Larson Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Jennifer C. Nelson Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Linda K. McEvoy Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Sundary Sankaran Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Dustin Key Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Jeremiah A. Litondo Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA; (A.R.); (M.L.); (J.A.M.); (T.S.D.); (B.K.L.); (K.M.); (E.B.L.); (J.C.N.); (L.K.M.); (S.S.); (D.K.); (J.A.L.)
Paul K. Crane School of Medicine, University of Washington, Seattle, WA 98195, USA;

Collapse

Jiang Q, Yang L, Chen ML, Hua F, Li JJ. Lipid Profile and Atrial Fibrillation: Is There Any Link? Rev Cardiovasc Med 2022;23:272. [PMID: 39076640 PMCID: PMC11266944 DOI: 10.31083/j.rcm2308272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 05/26/2022] [Accepted: 06/14/2022] [Indexed: 08/15/2023] Open

Ehlert AN, Heckbert SR, Wiggins KL, Thacker EL. Administrative billing codes accurately identified occurrence of electrical cardioversion and ablation/maze procedures in a prospective cohort study of atrial fibrillation patients. Clin Cardiol 2017;40:1227-1230. [PMID: 29214653 DOI: 10.1002/clc.22812] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Accepted: 09/07/2017] [Indexed: 11/11/2022] Open

Tan Q, Zhang S, Zou X, Zhao J, Hao J, Sun Q. Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients. Anatol J Cardiol 2017;18:103-107. [PMID: 28430117 PMCID: PMC5731256 DOI: 10.14744/anatoljcardiol.2017.7664] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/03/2017] [Indexed: 12/14/2022] Open

Abstract

OBJECTIVE

This study aimed to evaluate whether fluvastatin therapy could decrease the probability of atrial fibrillation (AF) progression from paroxysmal AF to permanent AF and decrease the recurrence frequency of AF.

METHODS

Analyses were performed using two-tailed Student's t test or Mann-Whitney U tests. Categorical variables were compared with the χ2 statistics or Fisher's exact test. Patients with paroxysmal AF were randomized case-control, prospective into either the fluvastatin group (n=61) or control group (n=57). Patients were followed up for 24 months. The primary endpoint event was paroxysmal AF that progressed to permanent AF. Secondary endpoints were AF recurrence, cardiac dysfunction, stroke, or death.

RESULTS

There were no differences in AF progression (fluvastatin group, 8.19% vs. control group, 12.51%; p>0.05) and stroke (fluvastatin group. 6.55% vs.

CONTROL GROUP

8.77%; p>0.05). Patients in the fluvastatin group had a lower rate of AF recurrence (fluvastatin group, 24.59% vs. control group, 49.12%; p<0.05) and a lower rate of cardiac dysfunction (fluvastatin group, 6.55% vs. control group, 19.29%; p<0.05). Death did not occur in both the groups. After 1 week of fluvastatin therapy, C-reactive protein (CRP) and homocysteine (HCY) levels were lower in the fluvastatin group than in the control group. At 24 months of follow-up, CRP and HCY levels remained lower in the fluvastatin group than in the control group. The number of endothelial progenitor cells (EPCs) increased in the fluvastatin group compared with that in the control group (fluvastatin group, 72.27±12.49 counts/105 vs. control group, 57.45±8.24 counts/105, p=0.001).

CONCLUSION

Fluvastatin therapy could not decrease AF progression. However, it could decrease the recurrence frequency of paroxysmal AF and cardiac dysfunction. This may occur because of depressing inflammation and improving circulating EPCs.

Collapse

ZHANG BEI, WANG XIMIN, LI ZHAN, WANG WEIZONG, ZHANG YONG, LIU JU, HOU YINGLONG. Atrial Heterogeneous Autonomic Neural Remodeling in Rabbits with Experimental Atrial Fibrillation and the Effect of Intervention by Rosuvastatin. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2016;39:598-606. [PMID: 27027580 DOI: 10.1111/pace.12859] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Revised: 03/10/2016] [Accepted: 03/20/2016] [Indexed: 11/30/2022]